This may be because these medication classes influence the secretion or action of endogenous insulin, processes potentially more adversely affected in type 3c diabetes than T2D, particularly in those with PEI where pancreatic damage may be more severe. This evidence concerns the gene INS and type 2 diabetes mellitus.